Trial Profile
The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer According to the BASQ Classification
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 30 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
- 12 Jul 2018 New trial record